Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.28), $0.06 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $65.08 million versus the consensus estimate of $70.82 million.

2017 Financial Guidance

• Ironwood continues to expect:
  • R&D expenses to be in the range of $145 million to $160 million.
  • SG&A expenses to be in the range of $235 million to $250 million.
  • the combined Allergan and Ironwood total 2017 marketing and sales expenses for LINZESS to be in the range of $250 million to $280 million.
  • net interest expense to be approximately $40 million.
  • to use less than $100 million in cash for operations in 2017

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.